A patient with the M2 subtype of AML who had a 45,X,−X,t(8;21) karyotype at diagnosis was found to have the Ph chromosome in one out of 37 evaluated cells 18 months after the initial diagnosis. Interphase FISH studies utilizing a BCR-ABL dual-color probe did not detect a fusion product 4 months prior to the appearance of one Ph-positive cell. Nineteen months post diagnosis and 5 months after clinical relapse all evaluated cells had the Ph chromosome in a clone characterized by t(8;21). These observations suggest that late appearing Ph is a secondary event which may be either therapy-related or consistent with one of the later events in a multistep pathogenesis of AML.
A late appearing Ph chromosome in chronic myelogenous leukemia (CML) is a rare but known clinical phenomenon. 1, 2 In acute myelogenous leukemia (AML), the late appearance of the Ph is an even more unusual event. [3] [4] [5] We recently studied a patient with the M2 subtype of AML and a 45,X,−X,t(8;21) karyotype at diagnosis who developed the Ph chromosome 18 months later. The BCR-ABL fusion product was not detected by interphase FISH analysis 4 months prior to the cytogenetically evident Ph chromosome.
AB was a 62-year-old woman who, in December 1992, had a routine complete blood count (CBC) which revealed a Hb of 13.1 gm/dl, a platelet count of 297 000/l and a WBC of 6800/l with 15% blasts, many of which contained Auer rods. A bone marrow aspirate contained 53% blasts, several of which contained Auer rods. Cytochemical studies revealed 98% peroxidase positivity, 91% SBB positivity and negative PAS, ABE and Tdt. A diagnosis of AML (FAB M2) was made and the patient received Ara-C and daunorubicin and entered remission. Her post-remission chemotherapy included Ara-C and daunorubicin followed by high-dose Ara-C. Her last course of chemotherapy was given in December 1993. A CBC performed in February 1994 revealed a WBC of 5500/l with 15% blasts. A bone marrow aspirate confirmed relapsed leukemia. Her subsequent therapy included high-dose Ara-C, etoposide and VP-16. In December 1994 she again relapsed and received supportive therapy with transfusions and hydroxyurea. She died of gram-negative sepsis on 9 February 1995. A summary of 13 cytogenetic studies is shown in Table 1 . In June 1994, 18 months after the initial diagnosis, one of the 37 evaluated metaphases (2.7%) had the Ph chromosome. The Ph chromosome was detected as a non-clonal abnormality in a clone characterized by t(8;21), and del(5)(p13). It was not detected in 24 examined cells from a direct preparation but among 13 evaluated cells from a 24-h culture. Twenty days later, all 11 examined cells from an unstimulated peripheral blood specimen were Ph-positive (Figure 1 ). PCR study performed at this time demonstrated the BCR rearrangement within the minor breakpoint region on chromosome 22 (data not shown). We undertook interphase FISH studies to determine if the BCR-ABL fusion product was present in nondividing cells prior to the detection of the Ph. Cells from the diagnostic cytogenetic specimen (December 1992) were not available. However, unmounted slides from the cytogenetic preparation at the time of first relapse (25 February 1994) (kept for 3 years at room temperature) showing only t(8;21), were destained and interphase FISH was performed with Vysis LSI BCR/ABL probe (Downers Grove, IL, USA). Of the 1004 evaluated nuclei, 16 cells (1.5%) showed BCR-ABL fusion signal. Remission specimens from August 1994 showed between 0.5% and 5% of cells with the fusion signal while blood cells at the time of relapse in December 1994, had 77% of cells with BCR-ABL fusion signal.
There are very few published studies examining the BCR gene in patients with Ph-negative AML and t(8;21). Simultaneous occurrence of the Ph chromosome in a cell clone showing t(8;21) was previously described in four patients with AML. [6] [7] [8] [9] Although the late appearance of the Ph chromosome in AML is unusual there are several documented cases in the literature, including two patients that we previously reported in whom the Ph first emerged during the first and second relapse, respectively. 4, 5, 10 To our knowledge the patient described in this report is the first patient with AML in whom the late appearance of the Ph and BCR-ABL fusion appeared in a clone characterized by t(8;21). The results of a literature survey of the molecular analysis of late appearing Ph chromosome in eight patients with AML are shown in Table 2 .
Dallorso et al 9 suggested that the loss of t(9;22) in a clone characterized by t(8;21) at the time of relapse in their patient strongly indicated that the Ph was a secondary abnormality. This study did not include molecular work. Sequential cytogenetic studies of our patient provides strong evidence that the Ph chromosome was also a secondary abnormality because it was detected for the first time as a non-clonal abnormality 18 months after the diagnosis of AML with −X, t(8;21) karyotype. The observation that remission was characterized by a normal karyotype and that PCR demonstrated a breakpoint in the minor bcr region represents further evidence in support of a diagnosis of AML and not CML. We cannot exclude the possibility that the Ph clone was present at diagnosis in a small number of cells which were not cytogenetically detectable. However, four subsequent chromosome analyses of 124 cells over a period of 18 months, including at relapse, did not reveal the Ph chromosome. Moreover, interphase FISH analysis of over 1000 nuclei 4 months prior to the cytogenetically evident Ph chromosome demonstrated 1.5% of cells with the 
Figure 1
A partial karyotype at relapse showing t(8;21) and t(9;22) occurring in the same bone marrow cell.
BCR-ABL fusion product. This is considered a negative result because the cut-off reference point for our laboratory is 2 ± 3.3% (mean, ± 3 s.d.) based on 15 330 studied cells from 91 normal controls. In five reported patients with AML and a late appearing Ph chromosome, RT-PCR assay did not detect a BCR-ABL fusion transcript at the time of diagnosis, but only concurrent with the cytogenetic appearance of the late appearing Ph chromosome. 4, [11] [12] [13] [14] A recent publication has suggested a possible causal relationship between chemotherapy with DNA topoisomerase II inhibitors and the subsequent development of leukemia with t(9;22). 15 In these 25 reported patients the latent period was between 4 and 192 months. Our patient was treated with daunorubicin and etoposide and therefore, we cannot exclude the possibility that this therapy may have been a contributing factor in the development of the late appearing Ph (18 months later). Alternatively, the development of late appearing Ph could be interpreted as one event in a multistep pathogenesis. Other observations published recently suggest that late appearing Ph chromosome in AML become cytogenetically evident between 17 and 36 months after diagnosis, during relapse in some patients (4/8 cases), usually in an already cytogenetically abnormal and therefore, unstable clone (6/8 cases) ( Table 2 ). The finding that 7/8 patients had P190
bcr-abl fusion transcript may be interpreted as consistent with its contribution to the terminal leukemogenic event. Whatever the cause may be, our observations suggest that the late appearing Ph chromosome in a patient with AML is a secondary event which may be either therapy-related or one of the later events in a multistep pathogenesis.
